津药药业子公司获盐酸甲氧氯普胺注射液药品注册证书

Core Viewpoint - The company has received approval for the drug Methochlorpromazine Hydrochloride Injection, which is primarily used as an antiemetic for various medical conditions [1] Group 1: Product Approval - The subsidiary Hubei Jinyao Pharmaceutical Co., Ltd. has obtained the Drug Registration Certificate from the National Medical Products Administration for Methochlorpromazine Hydrochloride Injection [1] - This injection is indicated for use in chemotherapy, radiotherapy, surgery, and conditions such as brain injuries and drug-induced vomiting [1] Group 2: Medical Applications - Methochlorpromazine Hydrochloride Injection is used for symptomatic treatment of nausea and vomiting associated with acute gastroenteritis, biliary and pancreatic diseases, and uremia [1] - It aids in diagnostic procedures such as duodenal intubation and reduces nausea during gastrointestinal barium X-ray examinations [1]